Raphael Pharmaceutical Stock Market Value
| RAPH Stock | 1.40 0.00 0.00% |
| Symbol | Raphael |
Raphael Pharmaceutical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Raphael Pharmaceutical's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Raphael Pharmaceutical.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Raphael Pharmaceutical on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Raphael Pharmaceutical or generate 0.0% return on investment in Raphael Pharmaceutical over 90 days. Raphael Pharmaceutical is related to or competes with Voyageur Pharmaceuticals, Avicanna, and Mydecine Innovations. More
Raphael Pharmaceutical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Raphael Pharmaceutical's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Raphael Pharmaceutical upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0758 | |||
| Maximum Drawdown | 86.67 |
Raphael Pharmaceutical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Raphael Pharmaceutical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Raphael Pharmaceutical's standard deviation. In reality, there are many statistical measures that can use Raphael Pharmaceutical historical prices to predict the future Raphael Pharmaceutical's volatility.| Risk Adjusted Performance | 0.0768 | |||
| Jensen Alpha | 1.01 | |||
| Total Risk Alpha | (0.18) | |||
| Treynor Ratio | (0.91) |
Raphael Pharmaceutical February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0768 | |||
| Market Risk Adjusted Performance | (0.90) | |||
| Mean Deviation | 2.6 | |||
| Coefficient Of Variation | 1193.17 | |||
| Standard Deviation | 11.15 | |||
| Variance | 124.28 | |||
| Information Ratio | 0.0758 | |||
| Jensen Alpha | 1.01 | |||
| Total Risk Alpha | (0.18) | |||
| Treynor Ratio | (0.91) | |||
| Maximum Drawdown | 86.67 | |||
| Skewness | 7.02 | |||
| Kurtosis | 56.36 |
Raphael Pharmaceutical Backtested Returns
Raphael Pharmaceutical appears to be out of control, given 3 months investment horizon. Raphael Pharmaceutical maintains Sharpe Ratio (i.e., Efficiency) of 0.0851, which implies the firm had a 0.0851 % return per unit of risk over the last 3 months. By analyzing Raphael Pharmaceutical's technical indicators, you can evaluate if the expected return of 0.96% is justified by implied risk. Please evaluate Raphael Pharmaceutical's Variance of 124.28, risk adjusted performance of 0.0768, and Coefficient Of Variation of 1193.17 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Raphael Pharmaceutical holds a performance score of 6. The company holds a Beta of -1.02, which implies a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Raphael Pharmaceutical are expected to decrease slowly. On the other hand, during market turmoil, Raphael Pharmaceutical is expected to outperform it slightly. Please check Raphael Pharmaceutical's treynor ratio and rate of daily change , to make a quick decision on whether Raphael Pharmaceutical's historical price patterns will revert.
Auto-correlation | 0.00 |
No correlation between past and present
Raphael Pharmaceutical has no correlation between past and present. Overlapping area represents the amount of predictability between Raphael Pharmaceutical time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Raphael Pharmaceutical price movement. The serial correlation of 0.0 indicates that just 0.0% of current Raphael Pharmaceutical price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.84 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Raphael OTC Stock
Raphael Pharmaceutical financial ratios help investors to determine whether Raphael OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Raphael with respect to the benefits of owning Raphael Pharmaceutical security.